Elanco Animal Health (NYSE:ELAN) Raised to Strong-Buy at Leerink Partnrs

Leerink Partnrs upgraded shares of Elanco Animal Health (NYSE:ELAN - Free Report) from a hold rating to a strong-buy rating in a research note issued to investors on Thursday morning,Zacks.com reports. Leerink Partnrs also issued estimates for Elanco Animal Health's Q4 2025 earnings at $0.15 EPS, FY2025 earnings at $0.85 EPS and FY2026 earnings at $0.95 EPS.

ELAN has been the topic of a number of other research reports. Leerink Partners raised Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price objective on the stock in a research report on Thursday. Wall Street Zen raised Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. William Blair raised Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Finally, Stifel Nicolaus increased their target price on Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a report on Wednesday, July 2nd. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $16.00.

Elanco Animal Health Trading Down 1.2%

ELAN traded down $0.18 during trading hours on Thursday, reaching $14.78. The company's stock had a trading volume of 3,045,323 shares, compared to its average volume of 5,032,333. Elanco Animal Health has a fifty-two week low of $8.02 and a fifty-two week high of $15.78. The stock has a market cap of $7.34 billion, a PE ratio of 19.97, a P/E/G ratio of 2.92 and a beta of 1.67. The business's 50-day moving average is $13.82 and its 200-day moving average is $11.79. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.71 and a quick ratio of 1.46.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, topping analysts' consensus estimates of $0.31 by $0.06. Elanco Animal Health had a return on equity of 7.54% and a net margin of 8.43%. The company had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.17 billion. During the same period in the prior year, the firm earned $0.34 earnings per share. The firm's revenue was down 1.0% compared to the same quarter last year. As a group, equities research analysts predict that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

Hedge funds have recently added to or reduced their stakes in the company. Proficio Capital Partners LLC purchased a new position in Elanco Animal Health in the fourth quarter valued at about $405,000. Raymond James Financial Inc. purchased a new position in Elanco Animal Health in the fourth quarter valued at about $10,561,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Elanco Animal Health in the fourth quarter valued at about $652,000. Swiss National Bank increased its holdings in Elanco Animal Health by 0.8% in the fourth quarter. Swiss National Bank now owns 972,292 shares of the company's stock valued at $11,774,000 after buying an additional 7,700 shares in the last quarter. Finally, Xponance Inc. increased its holdings in Elanco Animal Health by 20.6% in the fourth quarter. Xponance Inc. now owns 22,524 shares of the company's stock valued at $273,000 after buying an additional 3,851 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.